NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
-11.09%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.9B
AUM Growth
+$1.9B
(-10%)
Cap. Flow
+$40.1M
Cap. Flow
% of AUM
2.12%
Top 10 Holdings %
Top 10 Hldgs %
68.43%
Holding
55
New
7
Increased
8
Reduced
10
Closed
4
Top Buys
| 1 |
ASML
ASML
|
$144M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$141M |
| 3 |
Salesforce
CRM
|
$63.5M |
| 4 |
Arcellx
ACLX
|
$56.3M |
| 5 |
TSMC
TSM
|
$47.8M |
Top Sells
| 1 |
EXAI
Exscientia Plc American Depositary Shares
EXAI
|
$259M |
| 2 |
Vanguard Total Stock Market ETF
VTI
|
$93M |
| 3 |
Apple
AAPL
|
$53.8M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$16.7M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
$7.19M |
Sector Composition
| 1 | Healthcare | 48.98% |
| 2 | Technology | 19.33% |
| 3 | Financials | 8.72% |
| 4 | Consumer Discretionary | 2.87% |
| 5 | Communication Services | 1.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vanguard Total Stock Market ETF
VTI
$522B
| $347M | 18.32% |
1,525,550
-408,350
| -21% | -$93M |
|
2
Brookfield
BN
$99.2B
| $165M | 8.72% |
2,921,171
| – | – |
|
3
Boston Scientific
BSX
$158B
| $153M | 8.09% |
3,463,577
| – | – |
|
|
4
ASML
ASML
$285B
| $144M | 7.58% |
+215,099
| New | +$144M |
|
|
CTLT
5
DELISTED
CATALENT, INC.
CTLT
| $141M | 7.44% |
+1,271,707
| New | +$141M |
|
|
6
Apple
AAPL
$3.41T
| $107M | 5.63% |
610,879
-308,000
| -34% | -$53.8M |
|
|
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $65.6M | 3.46% |
1,634,811
-415,635
| -20% | -$16.7M |
|
|
8
Salesforce
CRM
$242B
| $63.5M | 3.35% |
+299,000
| New | +$63.5M |
|
|
9
Arcellx
ACLX
$3.87B
| $56.3M | 2.97% |
+4,016,878
| New | +$56.3M |
|
10
Alibaba
BABA
$330B
| $54.5M | 2.87% |
500,827
| – | – |
|
11
Edgewise Therapeutics
EWTX
$1.57B
| $54.2M | 2.86% |
5,587,207
| – | – |
|
12
Mirum Pharmaceuticals
MIRM
$3.73B
| $48.4M | 2.56% |
2,200,000
-245,147
| -10% | -$5.4M |
|
|
13
TSMC
TSM
$1.18T
| $47.8M | 2.52% |
+458,780
| New | +$47.8M |
|
14
Inogen
INGN
$219M
| $34.8M | 1.83% |
1,072,735
| – | – |
|
15
Nkarta
NKTX
$149M
| $31.8M | 1.68% |
2,793,863
-1
| -0% | -$11 |
|
16
Amicus Therapeutics
FOLD
$2.43B
| $24.2M | 1.28% |
2,560,211
| – | – |
|
17
Cable One
CABO
$891M
| $23.2M | 1.23% |
15,873
| – | – |
|
|
CYT
18
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $18.2M | 0.96% |
4,840,413
| – | – |
|
19
IO Biotech
IOBT
$110M
| $17.4M | 0.92% |
3,277,932
| – | – |
|
|
VERV
20
DELISTED
Verve Therapeutics
VERV
| $17.1M | 0.9% |
750,000
+50,000
| +7% | +$1.14M |
|
21
Insmed
INSM
$30.7B
| $16.6M | 0.88% |
705,838
+9,998
| +1% | +$235K |
|
22
Milestone Pharmaceuticals
MIST
$156M
| $16.2M | 0.86% |
2,530,003
-582
| -0% | -$3.74K |
|
|
VECT
23
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $15.9M | 0.84% |
3,380,402
-141,617
| -4% | -$667K |
|
24
LAVA Therapeutics
LVTX
$41M
| $14.6M | 0.77% |
3,327,312
| – | – |
|
|
BPMC
25
DELISTED
Blueprint Medicines
BPMC
| $14.5M | 0.77% |
227,526
+30,526
| +15% | +$1.95M |
|